Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin-12p70 and Early Secretory Antigen Target-6 fusion protein

Microbiology and Immunology

Volumn 55, Issue 11, 2011, Pages 798-808

  Deng, Yihao ^a   Bao, Lang ^a   Yang, Xiaoling ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Early Sectetary Antigen Target 6; Human Interleukin (IL 12) p70; Mycobacterium tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; RECOMBINANT BCG VACCINE EXPRESSING HUMAN INTERLEUKIN 12P70 EARLY SECRETORY ANTIGEN TARGET 6 FUSION PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; GENE CONSTRUCT; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INTERFERON PRODUCTION; LUNG PARENCHYMA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN; SPLEEN CELL; TH1 CELL; TUBERCULOSIS; WEIGHT GAIN;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; HISTOCYTOCHEMISTRY; IMMUNOGLOBULIN G; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; SPLEEN; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SYNTHETIC;

MUS; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS;

EID: 81155123220     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2011.00376.x     Document Type: Article

References (31)

1. WHO. (2009) Global tuberculosis control: A short update to the 2009 report. World Health Organization: 426.
2. Russell D.G., Barry C.E. 3rd, and Flynn J.L. (2010) Tuberculosis: what we don't know can, and does, hurt us. Science 328: 852-6.
3. Zodpey S.P. (2004) The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health 48: 70-7.
4. Dhar N., Rao V., and Tyagi AK. (2000) Recombinant BCG approach for development of vaccines cloning and expression of immunodominant antigens of M. tuberculosis. FEMS Microbiol Lett 190: 309-16.
5. + cells. Eur J Immunol 58: 57-65.
6. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., and Andersen P. (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047-55.
7. Mir F.A., and Kaufmann S.H., Eddine A.N. (2009) A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clin Vaccine Immunol 16: 1467-75.
8. Wang J., Qie Y., Zhu B., Zhang H., Xu Y., Wang Q., Chen J., Liu W., and Wang H. (2009) Evaluation of a recombinant BCG expressing antigAg85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Med Microbiol Immunol 198: 5-11.
9. Young S., O' Donnell M., Lockhart E., Buddle B., Slobbe L., Luo Y., De Lisle G., and Buchan G. (2002) Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2-and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol 80: 209-15.
10. Xu Y., Zhu B., Wang Q., Chen J., Qie Y., Wang J., Wang H. (2007) Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS Immunol Med Microbiol 51: 480-7.
11. Behr M.A., Wilson M.A., Gill W.P. Salamon H., Schoolnik G.K., Rane S., and Small P.M. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-3.
12. Harboe M., Oettinger T., Wiker H.G., Rosenkrands I., and Andersen P. (1996) Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 64: 16-22.
13. Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Young H.A., Wolf S.F., Young D., Clark S.C., and Trinchieri G. (1991) Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173: 869-79.
14. Gerosa F., Paganin C., Peritt D., Paiola F., Scupoli M.T., Aste-Amezaga M., Frank I., and Trinchieri G. (1996) Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon gamma and interleukin-10. J Exp Med 183: 2559-69.
15. Trinchieri G. (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-46.
16. Stover C.K., de la Cruz V.F., Fuerst T.R., Burlein J.E., Benson L.A., Bennett L.T., Bansal G.P., Young J.F., Lee M.H., and Hatfull G.F. (1991) New use of BCG for recombinant vaccines. Nature 351: 456-60.
17. Bao L., Chen W., Zhang H., and Wang X. (2003) Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guerin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis. Infect Immun. 71: 1656-61.
18. Chan J., Xing Y., Magliozzo R.S., and Bloom B.R. (1992). Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175: 1111-22.
19. + T cells following intranasal vaccination with recombinant bacteria. Infect Immun 76: 5817-25.
20. Feng C.G., Jankovic D., Kullberg M., Cheever A., Scanga C.A., Hieny S., Caspar P., Yap G.S., and Sher A. (2005) Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174: 4185-92.
21. Kaufmann S.H. 2006 Envisioning future stratedies for vaccination against tuberculosis. Nat Rev Immunol 6: 699-704.
22. Nathan C.F., Prendergast T.J., Wiebe M.E., Stanley E.R., Platzer E., Remold H.G., Welte K., Rubin B.Y., and Murray H.W. (1984) Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med 160: 600-5.
23. Hayashi D., Takii T., Fujiwara N., Fujita Y., Yano I., Yamamoto S., Kondo M., Yasuda E., Inagaki E., Kanai K., Fujiwara A., Kawarazaki A., Chiba T., and Onozaki K. (2001) Enhancement of innate immunity against Mycobacterium infection by immunostimulatory DNA is mediated by indoleamine2, 3-dioxygenase. Infect Immun 69: 6156-64.
24. Bai X., Wilson S.E., Chmura K., Feldman N.E., and Chan E.D. (2004) Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary. Tuberculosis (Edinb) 84: 375-85.
25. Rook G.A. 2007 Th2 cytokine in susceptibility to tuberculosis. Curr Mol Med. 7: 327-37.
26. Munk M.E., and Emoto M. (1995) Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl 20: 668s-75s.
27. + T cells to control of Mycobacterium tuberculosis infection. J Immunol 176: 4296-314.
28. Sugawara I., Sun L., Mizuno S., and Taniyama T. (2009) Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculsisi (Edinb) 89: 62-7.
29. Soualhine H., Deghmane A.E., Sun J., Mak K., Talal A., Av-Gay Y., and Hmama Z. (2007) Mycobacterium bovis Bacillus Calmette-Guerin secteting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages. J Immunol 179: 5137-45.
30. Hayashi T., Rao S.P., Takabayashi K., Van Uden J.H., Kornbuuth R.S., Baird S.M., Taylor M.W., Carson D.A., Catanzaro A., and Raz E. (2009) Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 56: 116-128.
31. Liu J., Tran V., Leung A.S., Alexander D.C., and Zhu B. (2009) BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Human Vaccine 5: 70-78.